Bobkova M.R. [HIV drug resistance]. Moscow: Chelovek, 2014. 288 p. (In Russ.).

2. Кравченко А.В., Кириченко А.А., Киреев Д.Е., Беляева В.В. Резистентность ВИЧ к антиретровирусной терапии. М.: ГЭОТАР-Медиа, 2023. 112 с. DOI: 10.33029/9704-7620-8-RAT-2023-1-112

Kravchenko A.V., Kirichenko A.A., Kireev D.E., Belуaeva V.V. [HIV resistance to antiretroviral therapy]. Moscow: GEOTAR-Media, 2023. 112 p. (In Russ.). DOI: 10.33029/9704-7620-8-RAT-2023-1-112

3. HIV-1 Drug Resistance in ARV-naive Populations. Compendium of published virus sequences from 95,024 persons, 442 studies according to region, year and subtype. https://hivdb.stanford.edu/_wrapper/surveillance/map/

4. Clutter D.S., Jordan M.R., Bertagnolio S., Shafer R.W. HIV-1 drug resistance and resistance testing. Infect. Genet. Evol. 2016; 46: 292–307. DOI: 10.1016/j.meegid.2016.08.031

5. Kirichenko A., Kireev D., Lapovok I., Shlykova A., Lopatukhin A., Pokrovskaya A. et al. HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006–2022. Viruses 2023; 15: 991. DOI: 10.3390/v15040991

6. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): 4724. DOI: 10.1371/journal.pone.0004724

7. May M., Sterne J.A., Sabin C., Costagliola D., Justice A.C., Thiebaut R. et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21(9): 1185–1197. DOI: 10.1097/QAD.0b013e328133f285

8. Sabin C.A., Smith C.J., Gumley H., Murphy G., Lampe F.C., Phillips A.N. et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004; 18(16): 2145–2151. DOI: 10.1097/00002030-200411050-00006

9. Scherrer A.U., Boni J., Yerly S., Klimkait T., Aubert V., Furrer H. et al. Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PLoS One 2012; 7(11): 50307. DOI: 10.1371/journal.pone.0050307

10. Lodi S., Günthard H.F., Gill J., Phillips A.N., Dunn D., Vu Q. et al. Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. J. Acquir. Immune. Defic. Syndr. 2019; 82(3): 314–320. DOI: 10.1097/QAI.0000000000002135

11. World Health Organization (WHO). Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV Interim guidance. 2018. WHO-update-of-recommendations-on-first-and-second-line-ARV-regimens pdf

12. Günthard H.F., Calvez V., Paredes R., Pillay D., Shafer R.W., Wensing A.M. et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clin. Infect. Dis. 2019; 68(2): 177–187. DOI: 10.1093/cid/ciy463

13. Scherrer A.U., Yang W.L., Kouyos R.D., Böni J., Yerly S., Klimkait T. et al. Swiss HIV Cohort Study. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. J. Infect. Dis. 2016; 214(3): 399–402. DOI: 10.1093/infdis/jiw165

14. Scherrer A.U., von Wyl V., Yang W.L., Kouyos R.D., Böni J., Yerly S. et al. Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin. Infect. Dis. 2016; 62(10): 1310–1317. DOI: 10.1093/cid/ciw128

15. Günthard H.F., Saag M.S., Benson C.A., del Rio C., Eron J.J., Gallant J.E. et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA 2016; 316(2): 191–210. DOI: 10.1001/jama.2016.8900

16. HIV drug resistance strategy, 2021 update. World Health Organization, 2021. https://www.who.int/publications/i/item/9789240030565

17. Guidelines on the public health response to pretreatment HIV drug resistance: July 2017. World Health Organization, 2017. https://www.who.int/publications/i/item/9789241550055

18. ВИЧ-инфекция у взрослых. Клинические рекомендации КР 79. М.: Национальная ассоциация специалистов по профилактике, диагностике и лечению ВИЧ-инфекции. Национальная вирусологическая ассоциация, 2020. 87 с. https://arvt.ru/sites/default/files/rf-2017-protokol-vich-vzroslie.pdf

[HIV infection in adults. Clinical guidelines KR 79]. Moscow, 2020. 87 p. (In Russ). https://arvt.ru/sites/default/files/rf-2017-protokol-vich-vzroslie.pdf

19. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(4, приложение): 92 с.

Pokrovskу V.V., Yurin O.G., Kravchenko A.V., Belyayeva V.V.. Buravtsova E.V., Deulina M.O. et al. [Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection]. Epidemiоlоgy and infectious diseases. Сurrent items 2021; 11(4, appendix): 92 р. (In Russ.).

20. Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe (Version 11.0; November 2021). Eur. AIDS Clin. Soc. http://www.eacsociety.org

21. Надзор за распространением штаммов ВИЧ, резистентных к антиретровирусным препаратам: Методические рекомендации МР 3.1.5.0075/1-13. М.: Федеральный центр гигиены и эпидемиологии Роспотребнадзора, 2014. 58 с.

[Surveillance of the spread of HIV strains resistant to antiretroviral drugs: Methodological recommendations MR 3.1.5.0075/1-13]. Moscow, 2014. 58 p. (In Russ.).

22. Tamura K., Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Molecular Biology and Evolution. 1993; (10): 512 –526.

23. Tamura K., Stecher G., Kumar S. MEGA 11: Molecular Evolutionary Genetics Analysis Version 11. Molecular Biology and Evolution 2021. DOI:10.1093/molbev/msab120

24. Paredes R., Tzou P.L., van Zyl G., Barrow G., Camacho R., Carmona S. et al. Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One 2017; 12(7): 0181357. DOI: 10.1371/journal.pone.0181357

25. Rhee S.Y., Taylor J., Fessel W.J., Kaufman D., Towner W., Troia P. et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother. 2010; 54(10): 4253–4261. DOI: 10.1128/AAC.00574-10

26. Lanier E.R., Ait-Khaled M., Scott J., Stone C., Melby T., Sturge G. et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 2004; 9(1): 37–45. DOI: 10.1177/135965350400900102

27. Azijn H., Tirry I., Vingerhoets J., de Béthune M.P., Kraus G., Boven K. et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents. Chemother. 2010; 54(2): 718–727. DOI: 10.1128/AAC.00986-09

28. Rhee S.Y., Liu T., Ravela J., Gonzales M.J., Shafer R.W. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob. Agents Chemother. 2004; 48(8): 3122–3126. DOI: 10.1128/AAC.48.8.3122-3126.2004

29. Reuman E.C., Rhee S.Y., Holmes S.P., Shafer R.W. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Antimicrob. Chemother. 2010; 65(7): 1477– 1485. DOI: 10.1093/jac/dkq140

30. Maldonado J.O., Mansky L.M. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations. Viruses 2018; 10(7): 376. DOI: 10.3390/v10070376